24.50GBp+2.51%Mkt Cap: 254.26M GBpP/E: —Last update: 2026-06-01
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phas…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap254.26M GBp
Enterprise Value255.64M GBp
Revenue (TTM)4.71M GBp
Gross Profit4.47M GBp
Net Income (TTM)-5.51M GBp
Revenue/Share0.0050 GBp
Last Price24.50 GBp
Fiscal Year EndApr 2025
MR QuarterOct 2025
Employees60
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.13
PEG—
EV/EBITDA-19.72
EV/Revenue54.26
P/S52.65
P/B-29.87
EPS (TTM)-0.01
EPS (Forward)-0.01
52W Range
7.85687% of range27.00
52W High27.00 GBp
52W Low7.856 GBp
Profitability
Gross Margin94.95%
Oper. Margin-283.34%
EBITDA Margin-275.17%
Profit Margin-116.98%
ROE—
ROA-52.17%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.40M GBp
CapEx (TTM)1.54M GBp
FCF Margin-363.38%
FCF Yield-6.73%
Net Debt7.61M GBp
Net Debt/EBITDA-0.59
Balance Sheet
Debt/Equity0.00
Current Ratio0.56
Quick Ratio0.56
Book Value/Sh-0.0080 GBp
Cash/Share0.0080 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split10:1
Split DateJul 26, 2011
Analyst Consensus
Rating—
Target (Mean)31.00 GBp
Target Range30.00 GBp – 32.00 GBp
# Analysts2
Ownership
Shares Out.1.04B
Float582.62M
Insiders3.65%
Institutions44.64%
Technical
SMA 5015.53 (+57.8%)
SMA 20011.98 (+104.5%)
Beta0.57
S&P 52W Chg27.94%
Avg Vol (30d)3.25M
Avg Vol (10d)5.26M
Technical Indicators
RSI (14)65.7
MACD2.5910
MACD Signal2.4393
MACD Hist.+0.1517
BB Upper27.74 GBp
BB Middle20.34 GBp
BB Lower12.94 GBp
BB Width72.77%
ATR (14)2.137 GBp
Vol Ratio (20d)0.28x